title: Improved prognosis of postoperative hepatocellular carcinoma patients when treated with functional foods: a prospective cohort study.
abstract: OBJECTIVE
  Active hexose correlated compound (AHCC) is a newly developed functional food. In vitro experiments have shown that AHCC enhances natural killer cell activity, and may be considered a potent biological response modifier in the treatment of cancer patients. However, the effects of AHCC in a clinical setting have not been reported. We seek to determine whether AHCC can improve the prognosis of hepatocellular carcinoma (HCC) patients following surgical treatment.
  
  
  METHODS
  A prospective cohort study was performed from February 1, 1992 to December 31, 2001. A total of 269 consecutive patients with histologically confirmed HCC were studied. All of the patients underwent resection of a liver tumor. Time to treatment failure (disease recurrence or death) and ten parameters related to liver function after surgery were examined.
  
  
  RESULTS
  Of the 269 patients, 113 received AHCC orally after undergoing curative surgery (AHCC group). The AHCC group had a significantly longer no recurrence period (hazard ratio (HR), 0.639; 95% confidence interval (CI), 0.429-0.952; P=0.0277) and an increased overall survival rate (HR, 0.421; 95% CI, 0.253-0.701; P=0.0009) when compared to the control group by Cox's multivariate analysis.
  
  
  CONCLUSIONS
  This study suggests that AHCC intake can improve the prognosis of postoperative HCC patients.
authors.affiliation: First Department of Surgery, Kansai Medical University, 10-15 Fumizono, Moriguchi, Osaka 570-8507, Japan. matsui@takii.kmu.ac.jp
authors.forename: Yoichi
authors.initials: Y
authors.lastname: Matsui
authors.forename: Junya
authors.initials: J
authors.lastname: Uhara
authors.forename: Sohei
authors.initials: S
authors.lastname: Satoi
authors.forename: Masaki
authors.initials: M
authors.lastname: Kaibori
authors.forename: Hitoshi
authors.initials: H
authors.lastname: Yamada
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kitade
authors.forename: Atsusi
authors.initials: A
authors.lastname: Imamura
authors.forename: Soichiro
authors.initials: S
authors.lastname: Takai
authors.forename: Yusai
authors.initials: Y
authors.lastname: Kawaguchi
authors.forename: A-Hon
authors.initials: AH
authors.lastname: Kwon
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Kamiyama
mesh_terms: D000284:Administration, Oral; D000368:Aged; D006528:Carcinoma, Hepatocellular / Q000178:diet therapy* / Q000401:mortality / Q000601:surgery; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D058870:Food, Organic; D006601:Hexoses / Q000008:administration & dosage; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage*; D008113:Liver Neoplasms / Q000178:diet therapy* / Q000401:mortality / Q000601:surgery; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011134:Polysaccharides / Q000008:administration & dosage; D011379:Prognosis; D011446:Prospective Studies
chemical_list: D006601:Hexoses; D007155:Immunologic Factors; D011134:Polysaccharides; C499366:Active Hexose Correlated Compound